Pharmaceutical suspension market to witness accelerated growth
The global pharmaceutical suspensions market is set to value $83.8 billion by 2032, due to the systems having key benefits such as supporting patient compliance.
List view / Grid view
The global pharmaceutical suspensions market is set to value $83.8 billion by 2032, due to the systems having key benefits such as supporting patient compliance.
Key opportunities within the small molecule active pharmaceutical ingredient (API) market include adopting continuous manufacturing and delving into niche disease areas, research has indicated.
Novartis has received a boost to its arsenal of cancer therapeutics after the FDA approved Pluvicto™ and complementary diagnostic imaging agent Locametz® to treat advanced prostate cancer.
Researchers anticipate the growth of the aging population and rising investment in biologic drugs to promote the expansion of the global active pharmaceutical ingredient (API) market.
At a recent event, pharmaceutical packaging experts discussed strategies to reduce waste and protect the bottom line.